共查询到20条相似文献,搜索用时 31 毫秒
1.
Fatemeh Bagheri Shahrokh Safarian Mohamadreza Baghaban Eslaminejad Nader Sheibani 《Cellular oncology (Dordrecht)》2013,36(6):515-526
Purpose
RNA interference (RNAi) has become a promising tool for cancer therapy. Small interfering RNAs (siRNAs) can synergistically enhance the cell killing effects of drugs used in cancer treatment. Here we examined the effects of siRNA-mediated DNA fragmentation factor 45 (DFF45) gene silencing on breast cancer cell viability, cell cycle arrest, and apoptosis in the presence and absence of doxorubicin.Methods
We designed three siRNAs, which target different regions of the DFF45 mRNA. Gene silencing was confirmed by real time RT-PCR and Western blot analyses. The impact of DFF45 siRNA, doxorubicin, and their combination on the viability, cell cycle and apoptosis of T-47D and MDA-MB-231 breast cancer cells were determined by MTT, PI staining, annexin V binding, caspase-3 activity, DNA laddering, and chromatin condensation assays.Results
Based on flow cytometric analyses, we found that silencing of DFF45 alone had little effect on apoptosis, especially in T-47D cells. However, when used in combination with doxorubicin (0.33 μM) a significant increase (P?<?0.05) in apoptosis was observed in T-47D and MDA-MB-231 cells, i.e., ~2.5- and 3-fold, respectively. Caspase-3 activity, chromatin condensation, as well as DNA laddering supported increased apoptosis in the combinatorial treatment. Cell cycle arrest in both cell lines occurred at lower levels after siRNA + doxorubicin treatment compared to doxorubicin only.Conclusions
Our data indicate that DFF45 gene silencing, when applied in combination with doxorubicin, may offer a novel therapeutic strategy for the treatment of breast cancer. 相似文献2.
Cao Yang Edwin Choy Francis J. Hornicek Kirkham B. Wood Joseph H. Schwab Xianzhe Liu Henry Mankin Zhenfeng Duan 《Cancer chemotherapy and pharmacology》2011,67(2):439-446
Purpose
To better understand the mechanisms of cytotoxicity and cell death induced by HDACI PCI-24781 in bone sarcoma cells.Methods
Four bone sarcoma cell lines were treated with PCI-24781, and the cytotoxicity was investigated. Further, accumulation of acetylated histones, p21, and PARP cleavage were evaluated in PCI-24781-treated cells. The synergistic effect of PCI-24781 to doxorubicin and its mechanism was investigated in bone sarcoma cells.Results
MTT assay demonstrated that the growth of bone sarcoma cells was inhibited after treatment with PCI-24781. Accumulation of acetylated histones, p21, and PARP cleavage were found in PCI-24781-treated cells. Expression of DNA repair protein RAD51 was inhibited, and the expression of apoptosis protein GADD45α was induced by PCI-24781 in bone sarcoma cells. Bone sarcoma cells treated with PCI-24781 become more sensitive to doxorubicin. The caspase-3/7 activity was increased with doxorubicin and PCI-24781 treatment in these cells.Conclusions
HDACI PCI-24781 has a synergistic effect on doxorubicin-induced apoptosis in bone sarcoma cells. 相似文献3.
Rhys D. Clyburn Penny Reid Catherine A. Evans Diane V. Lefley Ingunn Holen 《Cancer chemotherapy and pharmacology》2010,65(5):969-978
Purpose
Combination treatment using the chemotherapy drug doxorubicin and the anti-resorptive agent zoledronic acid has shown to be very effective in inducing apoptosis in breast cancer cells, and also to eradicate breast tumour growth in vivo. Here, we investigated whether apoptotic cell death is increased when zoledronic acid and doxorubicin are given in sequence or in combination in prostate cancer cells in vitro.Methods
PC3, DU145 and LNCaP prostate cancer cells were treated with zoledronic acid or doxorubicin alone, in sequence or in combination, and apoptosis was measured by evaluation of nuclear morphology following staining with Hoechst and PI. The involvement of the mevalonate pathway in the induction of apoptosis was assessed through the addition of the mevalonate pathway intermediate geranylgeraniol.Results
Both agents induced PC3 cell death, with 5 μM zoledronic acid inducing 1.73% apoptosis and 50 nM doxorubicin 3.60% apoptosis following 24 h of exposure. In contrast, sequential exposure (doxorubicin followed by zoledronic acid) caused 8.87% apoptosis. Doxorubicin followed by zoledronic acid induced 4.77% apoptosis in LNCaP cells, compared to 1.53% caused by zol alone, 2.23% by dox alone and 2.5% following the reverse sequence (P < 0.001 in all cases). In DU145 cells doxorubicin followed by zoledronic acid induced 5.73% apoptosis, compared to 1.8% following zol alone, 2.93% by dox alone, and 3.20% following the reverse sequence (P < 0.001 in all cases).Conclusions
This is the first detailed study to show that an increased anti-tumour effect is generated when doxorubicin and zoledronic acid are given in sequence in both hormone-sensitive and insensitive prostate cancer cells in vitro. Our results suggest that combined treatment with these agents is superior to single agent therapy, and should be explored in a tumour model of prostate cancer. 相似文献4.
M Hewish S A Martin R Elliott D Cunningham C J Lord A Ashworth 《British journal of cancer》2013,108(4):983-992
Background:
DNA mismatch repair deficiency is present in a significant proportion of a number of solid tumours and is associated with distinct clinical behaviour.Methods:
To identify the therapeutic agents that might show selectivity for mismatch repair-deficient tumour cells, we screened a pair of isogenic MLH1-deficient and MLH1-proficient tumour cell lines with a library of clinically used drugs. To test the generality of hits in the screen, selective agents were retested in cells deficient in the MSH2 mismatch repair gene.Results:
We identified cytarabine and other related cytosine-based nucleoside analogues as being selectively toxic to MLH1 and MSH2-deficient tumour cells. The selective cytotoxicity we observed was likely caused by increased levels of cellular oxidative stress, as it could be abrogated by antioxidants.Conclusion:
We propose that cytarabine-based chemotherapy regimens may represent a tumour-selective treatment strategy for mismatch repair-deficient cancers. 相似文献5.
José M. Silva Antonio Sánchez Celia Miralles Fátima Navarro Félix Bonilla 《Clinical & translational oncology》2000,2(3):141-145
Background
The present study was designed to investigate the possible impact of treatment on changes in plasma DNA showing tumor DNA features in breast cancer patients.Methods
Thirty-eight patients were included. DNA extracted from tumor and normal tissues, normal blood cells, and plasma was used for molecular studies. Molecular alterations in six polymorphic markers (TH2, D10S197, D16S421, D17S855, D17S654, D9S161), mutations in TP53, and aberrant methylation of the first exon of p16INK4a were used to characterize tumor and plasma DNA. After mastectomy, 26 patients received adjuvant chemotherapy and 12, hormone therapy.Results
At least one molecular alteration was detected in 28 tumors, and 9 patients showed more than one concomitant molecular change. Twenty patients (53%) displayed loss of heterozygosity (LOH), 6 (16%) TP53 mutations and 11 (29%) methylation of the first exon of p16INK4a. The same molecular aberration was observed in plasma DNA of 18 patients (14 receiving chemotherapy and 4 hormone therapy). Six months after mastectomy, these molecular alterations persisted in the plasma DNA of 6 patients (5 who had completed adjuvant chemotherapy and 1 under hormone therapy).Conclusions
Circulating plasma DNA present after mastectomy is modified only partially by adjuvant chemotherapy or hormone therapy. 相似文献6.
7.
Zhongyi Hu Denglu Zhang Jianrong Hao Keli Tian Wei Wang Hongxiang Lou Huiqing Yuan 《Cancer chemotherapy and pharmacology》2014,73(2):397-407
Purpose
Our previous studies had shown that Riccardin D (RD) exhibited cytotoxic effects by induction of apoptosis and inhibition of angiogenesis and topoisomerase II. Here, we reported that apoptosis is not the sole mechanism by which RD inhibits tumor cell growth because low concentrations of RD caused cellular senescence in prostate cancer (PCa) cells.Methods
Low concentrations of RD were used to treat PCa cells in vitro and in vivo, and senescence-associated β-galactosidase activity, DNA damage response markers, and/or colony-forming ability, cell cycle were analyzed, respectively. We then used siRNA knockdown to identify key factor in RD-triggered cellular senescence.Results
RD treatment caused growth arrest at G0/G1 phase with features of cellular senescence phenotype such as enlarged and flattened morphology, increased senescence-associated-beta-galactosidase staining cells, and decreased cell proliferation in PCa cells. Induction of cellular senescence by RD occurred through activation of DNA damage response including increases in the phosphor-H2AX, inactivation of Chk1/2, and suppression of repair-related Ku70/86 and phosphor-BRCA1 in PCa cells in vitro and in vivo. Analysis of expression levels of p53, p21CIP1, p16INK4a, p27KIP1, pRb and E2F1 and genetic knockdown of p21CIP1 demonstrated an important role of p21CIP1 in RD-triggered cellular senescence.Conclusions
Involvement of the DNA damage response and p21CIP1 defines a novel mechanism of RD action and indicates that RD could be further developed as a promising anticancer agent for cancer therapy. 相似文献8.
Background
Lapachol is a natural naphthoquinone compound that possesses extensive biological activities. The aim of this study is to investigate the inhibitory effects of lapachol on rat C6 glioma both in vitro and in vivo, as well as the potential mechanisms.Methods
The antitumor effect of lapachol was firstly evaluated in the C6 glioma model in Wistar rats. The effects of lapachol on C6 cell proliferation, apoptosis and DNA damage were detected by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)/ phenazinemethosulfate (PMS) assay, hoechst 33358 staining, annexin V-FITC/PI staining, and comet assay. Effects of lapachol on topoisomerase I (TOP I) and topoisomerase II (TOP II) activities were detected by TOP I and TOP II mediated supercoiled pBR322 DNA relaxation assays and molecular docking. TOP I and TOP II expression levels in C6 cells were also determined.Results
High dose lapachol showed significant inhibitory effect on the C6 glioma in Wistar rats (P?<?0.05). It was showed that lapachol could inhibit proliferation, induce apoptosis and DNA damage of C6 cells in dose dependent manners. Lapachol could inhibit the activities of both TOP I and II. Lapachol-TOP I showed relatively stronger interaction than that of lapachol-TOP II in molecular docking study. Also, lapachol could inhibit TOP II expression levels, but not TOP I expression levels.Conclusion
These results showed that lapachol could significantly inhibit C6 glioma both in vivo and in vitro, which might be related with inhibiting TOP I and TOP II activities, as well as TOP II expression.9.
Objective
The aim of our study was to investigate the effect of diallyl trisulfide (DATS) combining radiation on DNA injury-repair of Esophageal cancer EC109 cells.Methods
Using 10 and 20 μg/mL DATS on EC109 cells, and taking X-ray radiation 24 h later. Investigate the radiosensitization effect of DATS on EC109 cells by clone formation, and the mechanism of DNA injury-repair by Comet Assay.Results
The clone formation resulted that DATS had radiosensitization effect on EC109 cells. Radiosensitization enhancement ratios of 10 and 20 μg/mL DATS in combination with radiation were 1.55, 1.64 (Do) and 1.43, 1.75 (Dq) respectively. In the comet assay, the TM (tail moments) of 20 μg/mL DATS combining radiation group lines at 0 h, 2 h, 6 h and 24 h were 7.16 ± 2.61, 3.65 ± 2.06, 2.09 ± 0.83, 1.45 ± 1.37 respectively. They were slightly increased than radiation group (0.95 ± 0.65, 0.11 ± 0.07, 0.1 ± 0.05, 0.11 ± 0.08) and DATS group (1.81 ± 1.23, 1.58 ± 1.40, 0.45 ± 0.25, 0.60 ± 0.40) (P < 0.01). The result showed that DATS combining radiation had the effect of increasing DNA damage and inhibiting DNA repair on EC109 cells.Conclusion
DATS has radiosensitization effect on Esophageal cancer EC109 cells. And the effect is probably related with DNA injury-repair. 相似文献10.
Adrienne N. Howard Kathleen A. Bridges Raymond E. Meyn Joya Chandra 《Cancer chemotherapy and pharmacology》2009,65(1):41-54
Purpose
This study assessed the role of oxidative stress and loss of glutathione in ABT-737-induced apoptosis.Methods
Jurkat human acute lymphocytic leukemia cells and HeLa cells transfected with a tet-regulated Bcl-2 expression system were treated with ABT-737 or its less active stereoisomer. GSH concentrations, intracellular reactive oxygen species (ROS), caspase activation and apoptotic DNA fragmentation were measured.Results
ABT-737 induced oxidative stress through decreased GSH and increased intracellular hydrogen peroxide and superoxide levels. Apoptotic DNA fragmentation and caspase activation were the consequences of this oxidative stress. Combining ABT-737 with ROS-inducing agents such as adaphostin or etoposide enhanced cell death.Conclusions
These results demonstrate that inhibition of Bcl-2 causes a loss of GSH, an increase in ROS, caspase activation and subsequent apoptosis. Clinically, redox alterations as a consequence of Bcl-2 inhibition by ABT-737 should be considered in devising combination therapies with this novel agent or its derivatives. 相似文献11.
12.
Altered mucosal DNA methylation in parallel with highly active Helicobacter pylori-related gastritis
Takeichi Yoshida Jun Kato Takao Maekita Satoshi Yamashita Shotaro Enomoto Takayuki Ando Tohru Niwa Hisanobu Deguchi Kazuki Ueda Izumi Inoue Mikitaka Iguchi Hideyuki Tamai Toshikazu Ushijima Masao Ichinose 《Gastric cancer》2013,16(4):488-497
Background
Chronic inflammation triggered by Helicobacter pylori causes altered DNA methylation in stomach mucosae, which is deeply involved in gastric carcinogenesis. This study aimed to elucidate the correlation between altered mucosal DNA methylation levels and activity of H. pylori-related gastritis, because inflammatory activity shows particular correlations with the development of diffuse-type cancer.Methods
Methylation levels in stomach mucosae of 78 healthy volunteers were determined by real-time methylation-specific PCR or bisulfite pyrosequencing. Examined loci were the promoter CpG islands of six genes (FLNc, HAND1, THBD, p41ARC, HRASLS, and LOX) and the CpG sites of non-coding repetitive elements (Alu and Satα) that are reportedly altered by H. pylori infection. Activity of H. pylori-related gastritis was evaluated using two serum markers: H. pylori antibody titer and pepsinogen II.Results
Methylation levels of the six CpG islands were consistently increased, and those of the two repetitive elements were consistently decreased in a stepwise manner with the activity of gastric inflammation as represented by serum marker levels. Each serum marker level was well correlated with the overall DNA methylation status of stomach mucosa, and these two serologic markers were additive in the detection of the mucosa with severely altered DNA methylation.Conclusions
Alteration in mucosal DNA methylation level was closely correlated with activity of H. pylori-related gastritis as evaluated by serum markers. The observed correlation between altered DNA methylation levels and activity of H. pylori-related gastritis appears to be one of the relevant molecular mechanisms underlying the development of diffuse-type cancer. 相似文献13.
José Ricardo Scalise Regina Caeli Guerra Poças Thamy Pelatieri Caneloi Camila Oliveira Lopes Danilo Toshio Kanno Mayara Gonçalves Marques Júlio Cesar Martins Valdivia Felipe Rodrigues Maximo José Aires Pereira Marcelo Lima Ribeiro Denise Gonçalves Priolli 《Journal of gastrointestinal cancer》2016,47(4):409-416
Purpose
The ability to measure oxidative DNA damage in a tissue allows establishment of the relationship between DNA damage and mutations in normal and neoplastic cells. It is well known that TP53 is a key inhibitor of tumor development and preserves the genome integrity in each cell. The aim of the present study was to investigate the relationship between DNA damage and TP53 mutation in colorectal adenoma and adenocarcinoma, and the value of DNA damage as potential marker of TP53 mutation in non-tumor tissues adjacent to colon malignant lesions.Methods
Tissue samples were obtained by colonoscopy from patients with adenoma and/or adenocarcinoma and from healthy volunteers. Diagnosis was defined by histopathology. Immunohistochemistry with computer-assisted image analysis was performed to quantify TP53 mutation. Oxidative DNA damage was determined by comet assay. Statistical analyses were performed with 5 % of significance level.Results
The TP53 level was higher in non-tumor tissues from tumor patients than in normal tissues from healthy volunteers (p?=?0.01). Likewise, higher TP53 levels were observed in tumor tissues compared with the non-tumor tissues (p?=?0.00). Oxidative DNA damage levels were higher in tumor tissues than in non-tumor tissues (p?=?0.00). The amount of TP53 (p?=?0.00) and oxidative DNA damage (p?=?0.00) in normal and tumor tissue was related. The relationship between oxidative DNA damage and TP53 mutation was demonstrated in all samples (p?=?0.00).Conclusion
Oxidative DNA damage is an intervening variable for TP53 mutation in colorectal adenoma-carcinoma. Our data suggests that oxidative DNA damage is a potential marker of TP53 mutation in colorectal carcinogenesis.14.
15.
Ilaria Zanellato Carla Doriana Boidi Guido Lingua Pier-Giacomo Betta Sara Orecchia Elena Monti Domenico Osella 《Cancer chemotherapy and pharmacology》2011,67(2):265-273
Purpose
The present study addresses the optimization of gemcitabine?Ccisplatin protocols currently adopted in the clinical management of malignant pleural mesothelioma (MPM), using cell lines derived from different histological subtypes of MPM as an in vitro model.Methods
MPM cell lines were exposed either to single drugs or to their combinations, using a fixed dose ratio. Possible mechanisms for synergistic interactions were investigated by cell cycle analysis, western blot analysis of p53 phosphorylation status, and neutral comet assay to detect double strand breaks.Results
Four-hour pre-treatment with gemcitabine followed by 68-h exposure to cisplatin was found to exert synergistic activity in both epithelioid and sarcomatoid MPM subtypes, inducing a strong S-phase arrest that correlated with accumulation of double-strand breaks (DSBs).Conclusion
The antiproliferative effects of the gemcitabine/cisplatin combination in mesothelioma cells can be maximized by pre-treatment with gemcitabine, suggesting that this drug increases cisplatin-induced DSBs by inhibiting DNA adduct repair. 相似文献16.
Dirk Heshe Stephanie Hoogestraat Christine Brauckmann Uwe Karst Joachim Boos Claudia Lanvers-Kaminsky 《Cancer chemotherapy and pharmacology》2011,67(3):647-655
Purpose
The observation that the orphan drug dichloroacetate (DCA) selectively promotes mitochondria-regulated apoptosis and inhibits tumour growth in preclinical models by shifting the glucose metabolism in cancer cells from anaerobic to aerobic glycolysis attracted not only scientists??, clinicians?? but also patients?? interests and prompted us to further evaluate DCA effects against paediatric malignancies.Methods
The effects of DCA on mitochondrial membrane potential (????m), cell viability and induction of apoptosis were evaluated in paediatric tumour cell lines and the non-malignant cell line HEK293. In addition, combinations of DCA with the standard anticancer drugs cisplatin, doxorubicin, and temozolomide were tested and intra- and extra-cellular platinum species analysed.Results
DCA selectively induced phosphatidylserine externalisation and reduced ????m in paediatric tumour cells compared to HEK293 cells, but DCA concentrations ??10?mmol/L only moderately inhibited the growth of 18 paediatric tumour cell lines. DCA neither influenced the in vitro stability of cisplatin nor the cellular cisplatin uptake, but it abrogated the cytotoxicity of cisplatin in 7 out of 10 cell lines. DCA also affected the cytotoxicity of doxorubicin but did not influence the cytotoxicity of temozolomide. Despite phosphatidylserine externalisation, DCA failed to activate caspase 3/7 and, moreover, suppressed caspase 3/7 activation by cisplatin and doxorubicin.Conclusions
Our results indicate that apart from the intriguing effects of DCA on the glucose metabolism of cancer cells, the use of DCA for cancer treatment has to be evaluated carefully. Moreover, compassionate use of the orally available drug by patients with cancer themselves without medical supervision is strongly discouraged at present. 相似文献17.
18.
Hoo Hong Yong Sun Choi Hyuk Jin Cho Ji Youl Lee Joon Chul Kim Tae Kon Hwang Sae Woong 《中国癌症研究》2012,24(2):124-129
Objective: To investigate the antiproliferative effects of zinc‐citrate compound on hormone refractory prostate cancer (HRPC). Methods: HRPC cell line (DU145) and normal prostate cell line (RWPE-1) were treated with zinc, citrate and zinc-citrate compound at different time intervals and concentrations to investigate the effect of zinc-citrate compound. Mitochondrial (m)-aconitase activity was determined using aconitase assay. DNA laddering analysis was performed to investigate apoptosis of DU145 cells. Molecular mechanism of apoptosis was investigated by Western blot analysis of P53, P21 waf1 , Bcl-2, Bcl-xL and Bax, and also caspase-3 activity analysis. Results: Treatment with zinc-citrate compound resulted in a time-and dose-dependent decrease in cell number of DU145 cells in comparison with RWPE-1. M-aconitase activity was significantly decreased. DNA laddering analysis indicated apoptosis of DU145 cells. Zinc-citrate compound increased the expression of P21 waf1 and P53, and reduced the expression of Bcl-2 and Bcl-xL proteins but induced the expression of Bax protein. Zinc-citrate compound induced apoptosis of DU145 cells by activation of the caspase-3 pathway. Conclusion: Zinc-citrate compound can induce apoptotic cell death in DU145, by caspase-3 activation through up-regulation of apoptotic proteins and down-regulation of antiapoptotic proteins. 相似文献
19.
Oscar Krijgsman Daniëlle Israeli Hendrik F. van Essen Paul P. Eijk Michel L. M. Berens Clemens H. M. Mellink Aggie W. Nieuwint Marjan M. Weiss Renske D. M. Steenbergen Gerrit A. Meijer Bauke Ylstra 《Cellular oncology (Dordrecht)》2013,36(1):27-36
Background
Array Comparative Genomic Hybridization (aCGH) is a widely used technique to assess chromosomal copy number alterations. Chromosomal content, however, is often not uniform throughout cell populations. Here we evaluated to what extent aCGH can detect DNA copy number alterations in heterogeneous cell populations. A systematic evaluation is currently lacking, despite its importance in diagnostics and research. The detection limits reported are a compound of analytical software and laboratory techniques and do not account for the number of probes in relation to sample homogeneity.Methods
Detection limits were explored with DNA isolated from a patient with intellectual disability (ID) and from tumor cell line BT474. Both were diluted with increasing amounts of normal DNA to simulate different levels of cellularity. Samples were hybridized on microarrays containing 180,880 oligonucleotides evenly distributed over the genome (spacing ~17 kb).Results
Single copy number alterations, represented by down to 249 probes (4 Mb) and present in 10 % of a cell population, could be detected. Alterations encompassing as few as 14 probes (~238 Kb) could also be detected, but for this a 35 % mosaic level was required.Conclusions
DNA copy number alterations can be detected in cell populations containing 10 % abnormal cells. Detection of sub-megabase alterations requires a higher percentage of abnormal cells or microarrays with a higher probe density. 相似文献20.
Andre Luiz Mencalha B. Du Rocher D. Salles R. Binato E. Abdelhay 《Cancer chemotherapy and pharmacology》2010,65(6):1039-1046